Helminth Immunoregulation and Multiple Sclerosis Treatment

2016 ◽  
pp. 241-256
Author(s):  
Jorge Correale
Keyword(s):  
Multiple Sclerosis ◽  
Multiple Sclerosis Treatment

The possibility of venon usage in complex with other methods of multiple sclerosis treatment without medicament

1995 ◽  
Vol 56-63 ◽  
pp. 64-64
Author(s):  
N.G. Kochctkova ◽  
I.V. Krivopalov-Moskvin ◽  
L.Ya. Ebert
Keyword(s):  
Multiple Sclerosis ◽  
Multiple Sclerosis Treatment

scholarly journals Clinical efficacy and safety of alemtuzumab in postmarketing practice

2019 ◽  
pp. 56-62
Author(s):  
N. V. Khachanova
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Drug Efficacy ◽  
Safety Monitoring ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Treatment Benefit ◽  
Dosing Schedule ◽  
The World ◽  
Multiple Sclerosis Treatment

Clinical trials confirm alemtuzumab efficacy for multiple sclerosis treatment in terms of both conventional measures and combined criteria such as NEDA (no evidence of disease activity). However, established drug efficacy and convenient dosing schedule are balanced by the risk of serious adverse events. Therefore, it is necessary to inform physicians about the benefits of alemtuzumab therapy along with the pattern of its safety profile.The present review provides the analysis of alemtuzumab real-world studies in Europe, USA and other parts of the world. The information obtained can help physicians to prescribe and administer the drug properly and to perform effective safety monitoring for early detection of adverse events and saving the maximum treatment benefit for the patient.

Cancer after multiple sclerosis treatment in Mexican patients

2021 ◽  
Vol 429 ◽  
pp. 118194
Author(s):  
Marlene Arbeu Reyes ◽  
Brenda Bertado Cortés
Keyword(s):  
Multiple Sclerosis ◽  
Multiple Sclerosis Treatment ◽  
Mexican Patients

scholarly journals Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia

2020 ◽  
Vol 23 ◽  
pp. 13-18 ◽  
Author(s):  
Pieralessandro Lasalvia ◽  
Fabián Hernández ◽  
Camilo Castañeda-Cardona ◽  
J. Andrés Cuestas ◽  
Diego Rosselli
Keyword(s):  
Multiple Sclerosis ◽  
Cost Effectiveness ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Treatment
Sign in / Sign up

Export Citation Format

Share Document